Continuous subcutaneous insulin infusion in adult type 1 diabetes mellitus: data from a registry at the University Medical Centre Ljubljana, Slovenia.
To evaluate the treatment indications, effectiveness and adverse events of continuous subcutaneous insulin infusion (CSII) in adults with type 1 diabetes mellitus using data from a registry at the University Medical Centre Ljubljana, Ljubljana, Slovenia. The registry included patients with type 1 diabetes who had converted from multiple daily injection (MDI) to CSII. Patients with complete data sets covering a period of ≥3 years were included in the study (n=184). Complications, glycaemic control and insulin dose during CSII were compared with data obtained during MDI. CSII resulted in significant reductions in glycosyated haemoglobin level and total daily insulin dose. The mean number of severe hypoglycaemic episodes during CSII was 0.17 per patient per year. Treatment of adults with type 1 diabetes mellitus by CSII can improve glycaemic control and reduce insulin requirements compared with MDI, however patient selection, education and continuous care are important parts of this therapy.